SyVento and OncoArendi have signed a joint development collaboration and exclusive global licensing agreement for the use of the nanoliposomal formulation of the arginase inhibitor OATD-02.
Details in following press release.
March 13, 2024
SyVento BioTech at RNA Leaders ConferenceSyvento, a leading biotechnology company in RNA therapeutics, emerged at the recent RNA Leaders conference between March 13-14, 2024 in Basel, Switzerland. Throughout the event, Syvento showcased its innovative contributions to the field by exhibiting at booth no. 21. Visitors to the booth had the opportunity to engage with Syvento’s representatives, learn about the company’s […]